Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 3/20 | 0.35 |
| ▸ | HPGD | P15428 | 1/20 | 0.34 |
| ▸ | PABPC1 | P11940 | 1/20 | 0.34 |
| ▸ | APOBEC3A | P31941 | 1/20 | 0.34 |
| ▸ | APOBEC3G | Q9HC16 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.33 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.32 |
| ▸ | GSR | P00390 | 1/20 | 0.32 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.31 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.30 |
| ▸ | MAPT | P10636 | 1/20 | 0.30 |
| ▸ | HTT | P42858 | 1/20 | 0.30 |
| ▸ | MEN1 | O00255 | 1/20 | 0.30 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6435517 | 0.83 | CYP2C19 (0.42) | PABPC1APOBEC3AAPOBEC3GALDH1A1CYP3A4 | |
| SCHEMBL6434417 | 0.77 | CYP2C19 (0.34) | PABPC1APOBEC3AAPOBEC3GALDH1A1SLC6A4 | |
| SCHEMBL13189971 | 0.73 | LMNA (0.40) | LMNAHPGDPABPC1APOBEC3AAPOBEC3G | |
| SCHEMBL28568046 | 0.71 | FFAR1 (0.41) | — | |
| SCHEMBL11715129 | 0.70 | HPGD (0.45) | LMNAHPGDALDH1A1TRPA1 | |
| SCHEMBL6438865 | 0.70 | ALDH1A1 (0.33) | LMNAHPGDALDH1A1CYP3A4TRPA1 | |
| SCHEMBL25178092 | 0.70 | SIGMAR1 (0.40) | LMNAALDH1A1SLC6A4MAPTMEN1 | |
| SCHEMBL6435579 | 0.69 | ALDH1A1 (0.38) | LMNAHPGDPABPC1APOBEC3AAPOBEC3G | |
| SCHEMBL6435586 | 0.68 | ALDH1A1 (0.34) | LMNAHPGDALDH1A1TRPA1 | |
| SCHEMBL3241455 | 0.67 | LMNA (0.56) | LMNAHPGDPABPC1APOBEC3AAPOBEC3G |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6867323-B2 | Cross-coupling reaction of organosilicon nucleophiles | THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS (US) | 2005-03-15 | — | — | US | disclosed |
| US-20020183516-A1 | Cross-coupling reaction of organosilicon nucleophiles | UNIVERSITY OF ILLINOIS URBANA-CHAMPAIGN | 2002-12-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020183516-A1 | Cross-coupling reaction of organosilicon nucleophiles | TST, HPD, PCNA | LMNA 4232/4885HPGD 237/4885PABPC1 4414/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.